Ascentawits Pharmaceuticals

Ascentawits Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Ascentawits Pharmaceuticals (Shenzhen Ascenta Wits Pharmaceutical Technology Co., Ltd.) develops small molecule-drug conjugates as targeted cancer therapeutics. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma. The largest, NCT06245330 (A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumours), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.